Previous Close | 22.19 |
Open | 22.20 |
Bid | 23.65 x 1100 |
Ask | 23.69 x 1100 |
Day's Range | 21.92 - 24.42 |
52 Week Range | 5.84 - 24.42 |
Volume | |
Avg. Volume | 16,599,379 |
Market Cap | 1.721B |
Beta (5Y Monthly) | 0.63 |
PE Ratio (TTM) | 21.43 |
EPS (TTM) | 1.10 |
Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | May 16, 2022 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for SIGA
- IV TPOXX is an Important Option for Those Unable to Swallow – - Option to Fund Post-Marketing Field Study for IV TPOXX also Exercised – NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced the exercise of procurement options under its 75A50118C00019 (19C) contract with the U.S. Department of Health and Human Services for the delivery to the U.S. government of intravenous (IV) formulation of TPOXX t
The monkeypox outbreak has sent the drugmaker's stock up more than 200% this year, though its antiviral remains hard to access in the U.S.
The medicine Siga Technologies developed to combat biowarfare is now being used in the ongoing viral outbreak, and Siga stock has exploded.